Related Experiment Video
Updated: Aug 24, 2025
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma
Allison L Phillips1, David J Reeves1,2
1College of Pharmacy and Health Sciences, Butler University, Indianapolis, IN, USA.
Objective:
The aim of this article is to assess available data regarding use of nivolumab/relatlimab for adult and pediatric patients 12 years of age and older with unresectable or metastatic melanoma.
Data Sources:
A search of PubMed conducted from August 2019 to August 2022 with the search terms Opdualag, nivolumab AND relatlimab, and BMS-986016 resulted in 14 publications.
Study Selection And Data Extraction:
Relevant clinical trials written in English language were analyzed.
Data Synthesis:
Nivolumab/relatlimab was approved by the Food and Drug Administration following results of a phase 1/2 trial and phase 2/3 RELATIVITY-047 trial. Nivolumab/relatlimab demonstrated a median progression free survival (PFS) of 10.1 months in the first-line setting without new safety signals. The PFS benefits appear greatest in those with programmed cell death-ligand 1 (PD-L1) <1% and lymphocyte activation gene-3 (LAG-3) ≥1%. Adverse effects commonly experienced were immune related in nature and require early identification and prompt management. Grade 3 or 4 adverse effects occurred in 18.9% of patients.
Relevance To Patient Care And Clinical Practice:
For patients 12 years of age and older with unresectable or metastatic melanoma, nivolumab/relatlimab offers a new first-line treatment option. Evaluation of PD-L1 expression along with concomitant use of medications with potential interactions should be evaluated when deciding if nivolumab/relatlimab is the most appropriate treatment option.
Conclusions:
Nivolumab/relatlimab adds an additional first-line treatment option demonstrating promising improved PFS for patients with unresectable or metastatic melanoma, particularly those with PD-L1 <1% and/or LAG 3 ≥1%. Additional uses of nivolumab/relatlimab may be on the horizon as further clinical trials are ongoing.
Insights
Nivolumab/relatlimab is a new first-line treatment for unresectable or metastatic melanoma in patients 12 and older. It shows improved progression-free survival (PFS), especially in patients with low PD-L1 expression.
Area of Science:
- Oncology
- Immunotherapy
- Melanoma Treatment
Background:
- Metastatic melanoma remains a significant health challenge.
- Current treatment options have limitations in efficacy and safety profiles.
- The development of novel immunotherapies is crucial for improving patient outcomes.
Purpose of the Study:
- To assess available data on the use of nivolumab/relatlimab for unresectable or metastatic melanoma.
- To evaluate the efficacy and safety of nivolumab/relatlimab in adult and pediatric patients (12 years and older).
- To determine the role of nivolumab/relatlimab as a first-line treatment option.
Main Methods:
- A comprehensive literature search of PubMed was conducted from August 2019 to August 2022.
- Search terms included "Opdualag," "nivolumab AND relatlimab," and "BMS-986016."
- Relevant clinical trials published in English were analyzed.
Main Results:
- Nivolumab/relatlimab demonstrated a median progression-free survival (PFS) of 10.1 months in the first-line setting.
- PFS benefits were most pronounced in patients with programmed cell death-ligand 1 (PD-L1) <1% and lymphocyte-activation gene 3 (LAG-3) ≥1%.
- Common adverse effects were immune-related, requiring early identification and management; Grade 3 or 4 adverse effects occurred in 18.9% of patients.
Conclusions:
- Nivolumab/relatlimab represents a new first-line treatment option for unresectable or metastatic melanoma in patients aged 12 and older.
- Treatment decisions should consider PD-L1 expression and potential drug interactions.
- Ongoing clinical trials suggest potential for expanded future applications of nivolumab/relatlimab.
Related Concept Videos
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...